Skip to main content
SpringerLink
Log in

Therapy of mild to moderate colonic Crohn’s disease

  • Chapter
IBD 2007 — Achievements in Research and Clinical Practice

Part of the book series: Falk Symposium ((FASS,volume 159))

Abstract

Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing inflammatory process. It can affect any part of the gastrointestinal (GI) tract and is associated with transmural inflammation of the gut wall1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gionchetti P. Conventional therapy of Crohn’s disease. World J Gastroenterol. 2006;12:4794–806.

    Google Scholar 

  2. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006;73(Suppl. 1): 67–76.

    PubMed  CAS  Google Scholar 

  3. Stange EF, Travis SPL, Vermiere S et al. for the European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55(Suppl. I): i1–15.

    Article  PubMed  Google Scholar 

  4. Travis SPL, Stange EF, Lemann M et al. for the European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55(Suppl. I):i16–35.

    Article  PubMed  Google Scholar 

  5. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn’s is not a 6-week disease. A life long management of mild to moderate Crohn’s disease. Inflamm Bowel Dis. 2004:10:S2–10.

    Article  PubMed  Google Scholar 

  6. Gassull MA. The role of nutrition in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl. 4):79–83.

    Article  PubMed  CAS  Google Scholar 

  7. Zachos M, Tondeur M, Griffiths AM. Enteral nutrition therapy for induction of remission in Crohn’s disease (review). Cochrane Database of Systematic Reviews 2007; Issue 1.

    Google Scholar 

  8. Hanauer SB. Review article: Aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl. 4):60–5.

    Article  PubMed  CAS  Google Scholar 

  9. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:160–70.

    Article  PubMed  CAS  Google Scholar 

  10. Michetti P, Juillerat P, Mottet C et al. Therapy of mild to moderate luminal Crohn’s disease. Digestion. 2005;71:13–18.

    Article  PubMed  Google Scholar 

  11. Anthonisen P, Barany F, Folkenberg O et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn’s disease. A controlled double-blind study. Scand J Gastroenterol. 1974;9:549–54.

    PubMed  CAS  Google Scholar 

  12. Van Hees PA, Van Lier HJ, Van Elteren PH et al. Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut. 1981;22:404–9.

    Article  PubMed  Google Scholar 

  13. Summers RW, Switz DM, Sessions JT Jr et al. National Cooperative Crohn’s Disease Study: Results of drug treatment. Gastroenterology. 1979;77:847–69.

    PubMed  CAS  Google Scholar 

  14. Sandborn WJ, Feagan BG. Review article. Mild to moderate Crohn’s disease — defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18:263–77.

    Article  PubMed  CAS  Google Scholar 

  15. Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn’s Disease Study (ECCDS): Results of drug treatment. Gastroenterology. 1984;86:249–66.

    PubMed  CAS  Google Scholar 

  16. Hanauer SB. The case for using 5-aminosalicylates in Crohn’s disease. Pro. Inflamm Bowel Dis. 2005;11:609–12.

    Article  Google Scholar 

  17. Rasmussen SN, Lauritsen K, Tage-Jensen U et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22:877–83.

    Article  PubMed  CAS  Google Scholar 

  18. Mahida YR, Jewell DP. Slow release of 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion. 1990:45:88–92.

    Article  PubMed  CAS  Google Scholar 

  19. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278–82.

    Article  PubMed  CAS  Google Scholar 

  20. Bergman R, Parkes M. Systematic review: The use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841–55.

    Article  PubMed  CAS  Google Scholar 

  21. Gionchetti P, Rizzello F, Lammers KM et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006;12:3306–13.

    PubMed  CAS  Google Scholar 

  22. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion. 2006;73(Suppl. 1): 77–85.

    Article  PubMed  CAS  Google Scholar 

  23. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn’s disease: a double blind cross-over clinical trial. Scand J Gastroenterol. 1978;13:123–7.

    Article  PubMed  CAS  Google Scholar 

  24. Ambrose NS, Allan RN, Keighley MR et al. Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. A prospective randomized study. Dis Colon Rectum. 1985;28:81–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result. Gastroenterology. 1982;83:550–62.

    PubMed  CAS  Google Scholar 

  26. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut. 1991;32:1071–5.

    Article  PubMed  CAS  Google Scholar 

  27. Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328–32.

    PubMed  CAS  Google Scholar 

  28. Colombel JF, Lemann M, Cassagnou M et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94:674–8.

    Article  PubMed  CAS  Google Scholar 

  29. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol. 1998;12:53–6.

    PubMed  CAS  Google Scholar 

  30. Arnold GL, Beaves MR, Pryjdun VO, Mook VJ. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis. 2002;8:10–15.

    Article  PubMed  Google Scholar 

  31. Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology. 2002;123:33–40.

    Article  PubMed  CAS  Google Scholar 

  32. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol. 2005;17:145–7.

    Article  PubMed  CAS  Google Scholar 

  33. Wild GE. The role of antibiotics in the management of Crohn’s disease. Inflamm Bowel Dis. 2004;10:321–3.

    Article  PubMed  Google Scholar 

  34. Chopra A, Darrell SP, Loftus EV et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12:29–32.

    Article  PubMed  Google Scholar 

  35. Schölmerich J. Review article. Systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl. 4):66–74.

    Article  PubMed  Google Scholar 

  36. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews 2005; Issue 4.

    Google Scholar 

  37. Gross V, Andus T, Caesar I et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8:905–9.

    PubMed  CAS  Google Scholar 

  38. Bar-Meir S, Chowers Y, Lavy A et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. Israeli Budesonide Study Group. Gastroenterology. 1998;115:835–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine Division of Gastroenterology Inciraltı, Dokuz Eylül University School of Medicine, 35340, Izmir, Turkey

    H. A. Akpinar

Authors
  1. H. A. Akpinar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Marmara University, Istanbul, Turkey

    N. Tözün

  2. Yüksek İhtisas Hospital, Ankara, Turkey

    Ü. Dağlı

  3. Evangelismos Hospital, Athens, Greece

    G. Mantzaris

  4. Universität Regensburg, Regensburg, Germany

    J. Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer and Falk Foundation e.V.

About this chapter

Cite this chapter

Akpinar, H.A. (2008). Therapy of mild to moderate colonic Crohn’s disease. In: Tözün, N., Dağlı, Ü., Mantzaris, G., Schölmerich, J. (eds) IBD 2007 — Achievements in Research and Clinical Practice. Falk Symposium, vol 159. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6987-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-6987-1_22

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-6986-4

  • Online ISBN: 978-1-4020-6987-1

  • eBook Packages: Medicine (R0)

Publish with us

Policies and ethics

Search

Navigation